Richard Zeifman
Assistant Professor of Psychology and Director of PATH Lab
Key Impact
Investigates mechanisms of change in psychedelic therapy for depression, trauma, and suicidality.
Background & Research
Dr. Richard Zeifman leads the PATH Lab at The New School, focusing on the safety and efficacy of psychedelic-assisted therapy. As a licensed clinical psychologist and researcher, he conducts clinical trials and effectiveness studies to understand how psilocybin and MDMA promote psychological flexibility and long-term recovery in patients with MDD, cancer-related distress, and PTSD.
Collaboration Network
51 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Depressive DisordersAnxiety DisordersSuicidalityMajor Depressive Disorder (MDD)PTSDPalliative & End-of-Life DistressPersonality DisordersSubstance Use Disorders (SUD)Interpersonal Functioning & Social ConnectednessHealthy VolunteersNeuroimaging & Brain MeasuresPersonality & Trait FactorsBorderline Personality Disorder (BPD)Alcohol Use Disorder (AUD)SchizophreniaPublic Health, Prevention & Behaviour ChangeMicrodosingSafety & Risk ManagementChronic PainHealth Economics & ReimbursementEating DisordersAdolescentsBipolar DisorderObsessive-Compulsive Disorder (OCD)Treatment-Resistant Depression (TRD)Set & Setting